A Pharmacogenetic Study of <i>CYP2C19</i> in Acute Coronary Syndrome Patients of Colombian Origin Reveals New Polymorphisms Potentially Related to Clopidogrel Therapy

A Pharmacogenetic Study of <i>CYP2C19</i> in Acute Coronary Syndrome Patients of Colombian Origin Reveals New Polymorphisms Potentially Related to Clopidogrel Therapy

Clopidogrel, an oral platelet P2Y<sub>12</sub> receptor blocker, is used in the treatment of acute coronary syndrome. Interindividual variability in treatment response and the occurrence of adverse effects has been attributed to genetic variants in <i>CYP2C19</i>. The analysi...

Full description

Bibliographic Details
Main Authors: Mariana Angulo-Aguado, Karen Panche, Caroll Andrea Tamayo-Agudelo, Daniel-Armando Ruiz-Torres, Santiago Sambracos-Parrado, Maria Jose Niño-Orrego, Nathaly Páez, Laura B Piñeros-Hernandez, Luisa-Fernanda Castillo-León, Juan Mauricio Pardo-Oviedo, Katherine Parra Abaunza, Paul Laissue, Nora Contreras, Carlos Alberto Calderón-Ospina, Dora Janeth Fonseca-Mendoza
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Journal of Personalized Medicine
Subjects:
platelet reactivity
single-nucleotide variants
pharmacogenetics
acute coronary syndrome
clopidogrel
genotype
Online Access:https://www.mdpi.com/2075-4426/11/5/400

Internet

https://www.mdpi.com/2075-4426/11/5/400

Similar Items